BioSpace News Archive

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET.

60 Degrees Pharmaceuticals, Inc. announced the closing of its public offering of 5,260,901 units at a price to the public of $0.385 per Unit and 999,076 pre-funded units at a price to the public of $0.375 per Pre-Funded Unit.

AltaThera Pharmaceuticals will be presenting its data at the 29th Annual AF Symposium at the Omni Boston at the Seaport from February 1-3, where company representatives will be available to speak with directly at booth 503.

Ryvu Therapeutics (WSE: RVU) announced today that the first patient has been dosed with the study drugs in a Phase II clinical trial investigating RVU120 in combination with venetoclax for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) – the RIVER-81 study (NCT06191263).

By combining years of clinical experience with cutting-edge research and development, IlluminOss Medical announces it has received FDA 510(k) clearance for a new Light-Emitting Diode (LED) Console to speed curing of its patented, light-cured implants.

Compass Pathways plc announced that management will hold a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference at 2:00 pm ET on February 13, 2024.

Spero Therapeutics, Inc. announced that on January 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 50,000 restricted stock unit awards to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.

Aptose Biosciences Inc. announced the closing of the previously announced public offering of 5,649,122 common shares of the Company and warrants at a combined offering price of US $1.71 per share.

Viking Therapeutics, Inc. announced that the company will release financial results for the fourth quarter and year-end 2023 after the market close on Wednesday, February 7, 2024.

Ascendis Pharma A/S announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U.S. financial markets.